DDInter1082 DDInter1892
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Turmeric {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tenecteplase
Turmeric {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Turmeric may cause a minor interaction that can limit clinical effects when taken with Tenecteplase
Turmeric may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide